Iridex Corporation announced the successful enrollment of the first patient in the independent, investigator-led DAME Trial in the United Kingdom. This landmark study aims to evaluate MicroPulse® Technology as an adjunct to anti-vascular endothelial growth factor (anti-VEGF) therapy for severe Diabetic Macular Edema (DME).
Led by Professor Noemi Lois at Queen’s University Belfast, the trial is designed to enroll 264 participants across at least 20 clinical sites in the UK. The study will assess the clinical efficacy, safety, cost-effectiveness, and patient acceptability of adding subthreshold MicroPulse treatments.
The DAME Trial utilizes the Iridex IQ 577® laser in its MicroPulse® treatment mode, paired with the TxCell® Scanning Delivery Device. This research seeks to develop a new treatment pathway that could potentially reduce the number of anti-VEGF injections required, thereby lowering risks, inconvenience, and costs for patients and healthcare systems.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.